HistoGeneX Holding
Board
6 directors, 2 in day-to-day management, 1 auditor, no change since March 2026Chair of the board, director and managing director, permanent representative
chair of the board appointed by deed of 25-02-2016
director current term since 12-05-2021
6-year term from 2022
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 09-06-2026
Director
since 06-02-2025
term until 08-05-2030
listed in the 2025 annual accounts, filed on 09-06-2026
Director
since 08-07-2025
term until 14-05-2031
listed in the 2025 annual accounts, filed on 09-06-2026
Director and managing director, permanent representative
director appointed by deed of 19-02-2016
managing director appointed by deed of 25-02-2016
also on the board of 1 other company
- ,
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Two directors jointlydeed of 12-01-2026
Permanent representatives 2
Mandates through the years
18 names, the dashed line is todayDirector, Chair of the board, Managing director
Director
Director
Director
Director
Managing director
Statutory auditor
Director
Class B director
Day-to-day manager
Statutory auditor
Director
Director
Director
Director
Director
Director
Director
LeadershipBoardEarlierRest of the termmandate already running before its first mentionend not dated
Mandates as a list
-
- Director, appointed by deed of 19-02-2016, still in office
- Chair of the board, appointed by deed of 25-02-2016, still in office
- Managing director, appointed by deed of 25-02-2016, still in office
-
- Director, appointed by deed of 06-12-2023, still in office
-
- Director, since before 31-12-2024
-
- Director, since before 31-12-2024
-
- Director, appointed by deed of 12-01-2026, still in office
-
- Director, appointed by deed of 19-02-2016, until 11-03-2026
- Managing director, appointed by deed of 25-02-2016, still in office
-
- Statutory auditor, since before 31-12-2022
-
- Director, from before 31-12-2021 to 30-06-2025
-
- Class B director, appointed by deed of 09-09-2019, until 03-06-2025
- Chair of the board, appointed by deed of 09-09-2019, ended, last mentioned on 09-09-2019
-
- Class B director, appointed by deed of 09-09-2019, until 06-12-2023
- Day-to-day manager, appointed by deed of 09-09-2019, until 06-12-2023
-
- Statutory auditor, appointed by deed of 13-01-2017, until 18-01-2023
-
- Director, appointed by deed of 02-02-2018, until 01-08-2019
-
- Director, appointed by deed of 02-02-2018, until 01-08-2019
-
- Director, until 12-12-2017
-
- Director, appointed by deed of 27-10-2016, until 12-12-2017
-
- Director, appointed by deed of 19-02-2016, until 28-04-2016
-
- Director, appointed by deed of 01-12-2015, no longer listed in the 2025 annual accounts
-
- Director, appointed by deed of 01-12-2015, until 19-02-2016
Control
Parent
Equity €184.0m
Loss €30,967 in 2025 (loss €26,967 in 2024)
Checked score
100%
This company
HistoGeneX Holding
Equity €65.9m
Profit €24,715 in 2025
Further up the chain CA consolidates
Capital
- Capital
- €27,730,151
- Shares
- 27,730,151 in the 2025 annual accounts
- Contribution per share
- €1
- Equity per share
- €2.37 in 2025
- Source
- deed of 29-05-2020
Owners through the years
as the annual accounts name themOwners as a list
-
- 2019 to 2025: 100%
Source: parent in its own accounts, lists of holdings in the owners' accounts
Articles of association
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 21-08-2019 (in Dutch)
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 3 directorsdeed of 21-08-2019 (in Dutch)
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Artikel 10, Overdracht Aandelen en Overdracht Winstbewijzen onderworpen aan respectievelijke beperkingen artikel 10”“Prijs en voorwaarden, eigen_bericht_van_overdracht_en_procedure_artikel_10.4”“Prijs in Optie Kennisgeving, Aandelen waarvoor Optie uitgeoefend”“Overdracht Aandelen of Winstbewijzen in strijd met artikel 10, 10.8 Sanctie”deed of 14-08-2017 (in Dutch)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Wednesday of May at 21:00deed of 21-08-2019 (in Dutch)
- Dissolution ruleThe articles set when and by whom the company can be dissolved.
- “Desgevallend één of meer vereffenaars benoemd door algemene vergadering, besluit van algemene vergadering die beraadslaagt op wijze door wet…”deed of 21-08-2019 (in Dutch)
Shareholders
2 ownersOwners 2
- parentEquity €184.0m Loss of €30,967 in 2025 (loss of €26,967 in 2024) Checked scoreSourceaccounts 2025100%
- CAconsolidating parentconsolidates
Capital transactions
Shareholders according to the deeds
After the capital increase
deed of 29-05-2020 ↗
- 5,380,151 shares
Stated in the deed
deed of 29-05-2020 ↗
- all shares
Stated in the deed
deed of 09-09-2019 ↗
- all shares
At incorporation
deed of 01-12-2015 ↗
- sole founder · 100% at incorporation
Capital over time
- 29-05-2020 Capital increase of €5,380,151 · to €27,730,151 · 5,380,151 new shares · “inbreng door besloten vennootschap Arsenal IO Belgium,enige aandeelhouder,van zekere,vaststaande en opeisbare schuldvordering ten laste van de Vennootschap zoals beschreven in verslag commissaris”
- 21-08-2019 Capital stated in the deed · €22,350,000 · 22,350 shares
- 19-02-2016 Capital increase of €11,175,000 · to €22,350,000 · 11,175,000 new shares, 50% of the 22,350,000 shares after the increase · in kind
- 16-02-2016 Capital increase of €11,113,000 · to €11,175,000 · 11,113,000 new shares · in cash
- 01-12-2015 Incorporation · €62,000 · 62,000 shares